Protagonist Therapeutics Inc
PTGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.06B
Close$
$-4.09
103% downside
Current Fair Value
103% downsideOvervalued by 103% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.06 Billion |
|---|---|
| Enterprise Value | $8.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.05 |
| Beta | 1.79 |
| Outstanding Shares | 65,087,847 |
Return
| Return on Equity | -17.50% |
|---|---|
| Return on Assets | -16.45% |
| Return on Invested Capital | -20.55% |
Valuation & Multiples
| P/E Ratio | -78.2 |
|---|---|
| PEG | 59.04 |
| Price to Sales | - |
| Price to Book Ratio | 13.54 |
| Enterprise Value to Revenue | 499.44 |
| Enterprise Value to EBIT | -65.21 |
| Enterprise Value to Net Income | -78 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
$12.20 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$2.06
Average shareholder expectationRevenue Estimate
$200.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 23.35% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.33%▼ 123.54% |
|---|---|
| Total Invested | $26.04M▼ 99.69% |
| Investors Holding | 34▼ 297.00% |
ESG Score
No data
About Protagonist Therapeutics Inc
Relevant Senate Committees
Finance
Controls Medicare and Medicaid reimbursement rates and drug pricing legislation, directly determining the commercial viability of new drugs.
Health, Education, Labor, and Pensions
Directly oversees the FDA and NIH; controls the drug approval process and federal health research priorities.
Judiciary
Oversees intellectual property and patent law, which is the cornerstone of pharmaceutical valuation and market exclusivity.